Assignee
QURE BIOTECHNOLOGY SHANGHAI CO LTD
CN·1 granted patent·7 pending applications·0 citations·filing 2020–2023
Top patents by PatentIndex Score
8 records- 0145US2025206823A1Antigen targeting, anti-cd16a, and immune effector cell activating trifunctional fusion protein, and application thereofQURE BIOTECHNOLOGY SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0245US2024383985A1Antigen targeting, anti-cd16a, and immune effector cell activating trifunctional fusion protein, and application thereofQURE BIOTECHNOLOGY SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0344US2024294640A1Anti-cd3 antibody variant, fusion protein, and applicationQURE BIOTECHNOLOGY SHANGHAI CO LTD·Filed 2022·Application pending·0 cites
- 0444US2025326840A1BISPECIFIC ANTIBODY TARGETING SIRP-alpha AND PD-L1 OR ANTIGEN-BINDING FRAGMENT THEREOF AND USEQURE BIOTECHNOLOGY SHANGHAI CO LTD·Filed 2023·Application pending·0 cites
- 0537US2024018255A1ANTI-SIRPalpha ANTIBODY OR ANTIGEN-BINDING FRAGMENT THEREOF, AND USE THEREOFQURE BIOTECHNOLOGY SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 0636US2023183352A1Bispecific antibody targeting human claudin and human pdl1 proteins, and application thereofQURE BIOTECHNOLOGY SHANGHAI CO LTD·Filed 2021·Application pending·0 cites
- 0734US12516132B2Anti-PD-L1 nanobody and Fc fusion protein and application thereofQURE BIOTECHNOLOGY SHANGHAI CO LTD·Filed 2020·Granted Jan 6, 2026·0 cites·12 claims
- 0832US2022235128A1Anti-cldn antibody and pharmaceutical composition thereof and detection method thereforQURE BIOTECHNOLOGY SHANGHAI CO LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when QURE BIOTECHNOLOGY SHANGHAI CO LTD files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →